BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals in Cleveland. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.
BioMotiv is advancing a portfolio of discoveries into new medicines through an innovative model that efficiently aligns capital and collaborations for the benefit of inventors and investors, and ultimately physicians and patients. Therapeutic opportunities are identified by BioMotiv through relationships with the Harrington Discovery Institute, universities and research institutions, disease foundations, and industry sources. BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.